PT  - JOURNAL ARTICLE
AU  - Mansoor Ahmed
AU  - Michael Luggen
AU  - Jerome H Herman
AU  - Kenneth L Weiss
AU  - Gabrielle Decourten-Myers
AU  - John G Quinlan
AU  - Dinesh Khanna
TI  - Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration.
DP  - 2006 Nov 01
TA  - The Journal of Rheumatology
PG  - 2344--2346
VI  - 33
IP  - 11
4099  - http://www.jrheum.org/content/33/11/2344.short
4100  - http://www.jrheum.org/content/33/11/2344.full
SO  - J Rheumatol2006 Nov 01; 33
AB  - Tumor necrosis factor-a (TNF-a) inhibition, used in the treatment of rheumatoid arthritis (RA), is associated with central nervous system (CNS) events including new onset and/or exacerbations of pre-existing demyelinating neurological diseases. We describe a patient with refractory RA where adalimumab, a fully humanized IgG1 monoclonal antibody against TNF-a, may have contributed to the development of meningoencephalitis, with brain biopsy suggestive of hypertrophic pachymeningitis, a rare complication of this disease. The patient had recurrence of neurological symptoms upon repeated administration of adalimumab, and resolution of symptoms after withdrawal.